In conclusion, we recommend in gastric cancer patients with malignant ascites or a pleural effusion that a repeat HER2 assessment of the CB-ME is considered when the initial primary gastric adenocarcinoma is HER2 negative. The gene discussed is ERBB2; the disease is gastric adenocarcinoma.